Stockreport

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs [Yahoo! Finance]

Alzamend Neuro, Inc.  (ALZN) 
PDF Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash Strengthened balance sheet in preparation for five clinical trials to be initia [Read more]